Study of the depressive disorders in patients with myasthenia gravis
DOI:
https://doi.org/10.15587/2519-4798.2018.121973Keywords:
myasthenia, depression, antibodies, acetylcholine receptors, muscle-specific tyrosine-kinase, ophthalmic form, generalized formAbstract
Aim of the research: To study depressive manifestations in patients with myasthenia depending on the duration, clinical form and immunological type of the disease.
Methods: A neurological examination, determination of antibodies to acetylcholine receptors and muscle-specific tyrosine-kinase, a Beck depression score of 96 patients with myasthenia was performed.
Results: The average age of patients was 50.5±12.4 years, the average duration of the disease was 4.4±1.2 years. Antibodies to acetylcholine receptors were detected in 57 (80.3 %) of 71 patients with generalized form and in 13 (52 %) of 25 patients with ophthalmic myasthenia. In 6 (8.5 %) of 71 patients with generalized myasthenia, antibodies to muscle-specific tyrosine-kinase were detected. In 8 (11.3 %) out of 71 patients with a generalized form of myasthenia and 12 (48.0 %) out of 25 patients with an ocular form of myasthenia antibodies were not detected. Depressive manifestations in the form of mild (32 persons) and moderate (34 persons) depression were detected in 66 patients, the mean score on the Beck scale was 12.9±3.45 points). In patients with a generalized form of myasthenia, the incidence of mild to moderate depression does not significantly differ, with no significant difference in the average duration of the disease in these groups of patients. At the same time, in patients with generalized myasthenia without manifestations of depression, the average duration of the disease was significantly lower. The presence and degree of manifestations of depressive disorders does not depend on the presence of antibodies to the receptors of acetylcholine, antibodies to muscle-specific tyrosine-kinase or their absence.
Conclusions: As a result of the work, it was found that the development of depressive disorders in patients with myasthenia increases with the duration of the disease. Depressive manifestations are more pronounced in patients with generalized myasthenia in compare to patients with ophthalmic form.
The development and degree of depressive manifestations does not depend on the immune type of myastheniaReferences
- Kulikova, S. L. (2014). Antitela k atsetilholinovyim retseptoram v diagnostike razlichnyih form miastenii. Nevrologiya i neyrohirurgiya Vostochnaya Evropa, 1 (21), 73–82.
- Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L. et. al. (2010). Guidelines for treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology, 17 (7), 893–902. doi: 10.1111/j.1468-1331.2010.03019.x
- Shkolnik, V. M., Kalbus, A. I., Baranenko, A. N., Pogorelov, A. V. (2014). Miasteniya: sovremennyie podhodyi k diagnostike i lecheniyu. Ukrainskyi nevrolohichnyi zhurnal, 2, 12–17.
- Shkolnik, V. M., Kalbus, A. I., Shulga, O. D. (2010). Miasteniya: chto nam izvestno segodnya? Zdorov’ya Ukrayiny (nevrologiya, psyhiatriya, psyhoterapiiya), 3 (14), 10–11.
- Shulga, O. D., Kalbus, A. I., Shulga, L. A. (2010). Miasteniya. Neyron Revyu, 2, 13–20.
- Kulaksizoglu, I. B. (2007). Mood and Anxiety Disorders in Patients with Myasthenia Gravis. CNS Drugs, 21 (6), 473–481. doi: 10.2165/00023210-200721060-00004
- Aysal, F., Karamustafalioglu, O., Ozcelik, B., Yilmaz, M., Karamustafalioglu, N., Yumrukcal, H., Tankaya, O. (2013). The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Archives of Neuropsychiatry, 50 (4), 295–300. doi: 10.4274/npa.y5611
- Gulec Uyaroglu, F., Bilgin, S., Keles, E. H., Zorlu, Y. (2016). Anxiety And Depression Symptoms In Patients With Generalized Myasthenia Gravis. The Journal of Tepecik Education and Research Hospital, 26 (2), 97–103 doi: 10.5222/terh.2016.097
- Suzuki, Y., Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Kabasawa, C. et. al. (2011). Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open, 1 (2), 1–7. doi: 10.1136/bmjopen-2011-000313
- Blum, S., Lee, D., Gillis, D., McEniery, D. F., Reddel, S., McCombe, P. (2015). Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience, 22 (7), 1164–1169. doi: 10.1016/j.jocn.2015.01.022
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Oleksandr Kalbus
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
